A Study to Evaluate the Ease of Use, Local Tolerance, Safety and Effectiveness of Gonal-f® (Filled-by-mass in a Prefilled Pen)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck KGaA
ClinicalTrials.gov Identifier:
NCT01115725
First received: April 30, 2010
Last updated: December 4, 2012
Last verified: December 2012
  Purpose

This is a prospective, open-label, non-comparative, multicentric Phase 4 study to evaluate the ease of use, local tolerance, safety and effectiveness of Gonal-f® (filled-by-mass in a prefilled pen) in subjects undergoing ovarian hyperstimulation for in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) with recombinant follicle stimulating hormone (r-FSH).

Clarification for change of study type:

The study was erroneously registered as an interventional trial on ClinicalTrials.gov between 2010 and 2012. It was shown recently that the study protocol and conduct of the study did not include any clinical interventions beyond those which are Standard Clinical Practice and the approved label for Gonal-f®. Furthermore, all other relevant study essential documentations (e.g. Informed Consent, CRF, etc.) are in line with an observational study design. As per EU regulations (Article 2(c) of Directive 2001/20/EC), this study is a 'non-interventional trial'.


Condition Intervention Phase
Infertility
Drug: Gonal-f® (follitropin alfa)
Phase 4

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Phase IV Study to Evaluate the Ease of Use, Local Tolerance Safety and Effectiveness of Gonal-f® (Filled-by-Mass in a Prefilled Pen)

Resource links provided by NLM:


Further study details as provided by Merck KGaA:

Primary Outcome Measures:
  • Convenience assessment [ Time Frame: Post-treatment assessment (35-42 days post embryo transfer) ] [ Designated as safety issue: No ]
    Subjects' to complete ease questionnaire survey for use of Gonal-f prefilled pens.


Secondary Outcome Measures:
  • Efficacy assessments [ Time Frame: Pre-study (within 3 months prior to study start) to days 35-42 post-hCG ] [ Designated as safety issue: No ]
    Secondary efficacy assessments include evaluation of the duration of stimulation; total amount of gonadotropins needed; number of follicles on the day of the last ultra-sound scan; estradiol (E2) on the day of the last ultra-sound scan; number of oocytes retrieved; number of oocytes fertilised; number of embryos transferred; clinical pregnancy by ultra-sound scan

  • Safety and tolerance assessments [ Time Frame: First stimulation day (S1) to days 15-20 post-hCG ] [ Designated as safety issue: Yes ]
    Safety will be measured by the incidence and severity of adverse events (AEs) including local reactions; and incidence of ovarian hyperstimulation syndrome (OHSS)


Enrollment: 76
Study Start Date: November 2005
Study Completion Date: July 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Gonal-f® prefilled pen Drug: Gonal-f® (follitropin alfa)
Gonal-f® (follitropin alfa) will be given once daily subcutaneously at a starting dose of 150-375 international unit per day (IU/day) by self-administered injection via a pen device for first 5 days. After Day 5, Gonal-f® dose will be adjusted according to the investigator's discretion until ovarian response observed.
Other Name: Recombinant human follicle stimulating hormone (r-hFSH)

Detailed Description:

Treatment of subfertility and infertility by assisted reproduction technologies (ART) such as IVF and embryo transfer (ET) requires multiple follicular development to increase the number of female gametes, and the chances of a successful treatment outcome. Ovarian stimulation in IVF or ICSI currently includes suppression of endogenous luteinizing hormone (LH) secretion by administration of a gonadotropin releasing hormone (GnRH) agonist, followed by stimulation of multiple follicular development by exogenous FSH administration. When adequate follicular development is achieved, a single dose of u-hCG (urinary-human chorionic gonadotropin) is administered to mimic the endogenous LH surge and induce final oocyte maturation. Recombinant-human FSH (r-hFSH) has been shown to be superior to u-hFSH (urinary-derived FSH) in terms of requiring fewer ampoules and more efficacious in terms of number of oocytes recovered and in terms of pregnancy rates.

Recently, a new formulation of follitropin alfa has been developed as the next step in innovation in Serono capitalized on the fact that Serono recognized that follitropin alfa manufacturing was highly controlled and with a controlled specific activity that allowed filling the product by mass guaranteeing the dose being delivered. Until now follitropin alfa has been produced as a lyophilisate for injection (either as single dose or multidose applications) in glass ampoules or in glass vials and administered using syringes. Today, Gonal-f® fill-by-mass is available as a new liquid formulation that can be administered with the pen device which is prefilled and hence the subject does not have to assemble the device making it simpler to use.

OBJECTIVES

Primary objective:

To evaluate the ease-of-use of Gonal-f® (filled by mass in a prefilled pen) in subjects undergoing IVF/ICSI.

Secondary objectives:

To evaluate the local tolerance, safety and effectiveness of Gonal-f® prefilled pens.

  Eligibility

Ages Eligible for Study:   18 Years to 39 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Primary care clinic

Criteria

Inclusion Criteria:

  • Pre-menopausal female subjects, between their 18th and 39th birthday
  • Subjects with body mass index between 18-32 kilogram per square meter (kg/m^2)
  • Subjects with FSH (on second day of menstrual cycle) less than 10 milli international unit per milliliter (mIU/ml)
  • Subjects who required treatment with recombinant FSH for controlled ovarian hyperstimulation for IVF and/or ICSI
  • Subjects who are able to communicate well with the investigator and to comply with the requirements of the entire study
  • Subjects who have given written informed consent, prior to treatment, with the understanding that consent may be withdrawn by the subject at any time without prejudice

Exclusion Criteria:

  • Subjects who are not pregnant or lactating
  • Subjects with known allergic reaction against one of the ingredients
  • Subjects with enlarged ovaries or cysts unrelated to polycystic ovaries (PCO)
  • Subjects with gynecological bleeding of unknown origin
  • Subjects who have ovarian, uterine, or mammary cancer
  • Subjects with hyperprolactinemia
  • Subjects with tumors of the hypothalamus or the pituitary gland
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01115725

Locations
Greece
EMBRYOGENESIS IVF Unit
Athens, Kifisias aV, Greece, 151 25
Sponsors and Collaborators
Merck KGaA
Investigators
Study Director: Study Director Merck A.E. Hellas, an affiliate of Merck KGaA, Darmstadt, Germany
  More Information

No publications provided

Responsible Party: Merck KGaA
ClinicalTrials.gov Identifier: NCT01115725     History of Changes
Other Study ID Numbers: IMP25404
Study First Received: April 30, 2010
Last Updated: December 4, 2012
Health Authority: Greece: National Organization of Medicines

Keywords provided by Merck KGaA:
Follitropin alfa
Fertilization in vitro
Intracytoplasmic sperm injection
Reproductive techniques, assisted

Additional relevant MeSH terms:
Infertility
Genital Diseases, Male
Genital Diseases, Female
Follicle Stimulating Hormone
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 15, 2014